Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences (DE:2Q5)
FRANKFURT:2Q5
Holding DE:2Q5?
Track your performance easily
2Q5 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.39 - €4.84
Previous Close€0.39
Volume0.00
Average Volume (3M)5.22K
Market Cap
€66.47M
Enterprise Value€73.91M
Total Cash (Recent Filing)$312.70K
Total Debt (Recent Filing)$8.57M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
May 15, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding147,504,944
10 Day Avg. Volume522
30 Day Avg. Volume5,220
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.34
Price to Sales (P/S)201.79
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue240.51
Enterprise Value/Gross Profit209.55
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renovaro Biosciences News
Options Prices
Currently, No data available
---
Ownership Overview
73.73% Insiders
4.64% Mutual Funds
4.94% Other Institutional Investors
16.68% Public Companies and
Individual Investors
2Q5 FAQ
What was Renovaro Biosciences’s price range in the past 12 months?
Renovaro Biosciences lowest stock price was €0.39 and its highest was €4.84 in the past 12 months.
What is Renovaro Biosciences’s market cap?
Currently, no data Available
When is Renovaro Biosciences’s upcoming earnings report date?
Renovaro Biosciences’s upcoming earnings report date is May 15, 2023 which is 501 days ago.
How were Renovaro Biosciences’s earnings last quarter?
Renovaro Biosciences released its earnings results on Feb 13, 2023. The company reported -€0.072 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.072.
Is Renovaro Biosciences overvalued?
According to Wall Street analysts Renovaro Biosciences’s price is currently Overvalued.
Does Renovaro Biosciences pay dividends?
Renovaro Biosciences does not currently pay dividends.
What is Renovaro Biosciences’s EPS estimate?
Renovaro Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renovaro Biosciences have?
Renovaro Biosciences has 147,504,940 shares outstanding.
What happened to Renovaro Biosciences’s price movement after its last earnings report?
Renovaro Biosciences reported an EPS of -€0.072 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Renovaro Biosciences?
Currently, no hedge funds are holding shares in DE:2Q5
---
Renovaro Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.99%
12-Months-Change
Fundamentals
Return on Equity
-87.88%
Trailing 12-Months
Asset Growth
126.20%
Trailing 12-Months
Company Description
Renovaro Biosciences
Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.
---
Technical Analysis
Renovaro Biosciences
―
Inmune Bio
―
Adaptimmune Therapeutics
―
Oncternal Therapeutics
―
Kintara Therapeutics
―
---